🧬Genentech – Oncology R&D Division Template 20260427T224911Z 20260501T225611Z David Nagy
β€Š

Link from the organization's website
Download this template for import into Evernote. But note that Evernote export files do not include internal notebook links, which would need to be relinked after import into Evernote.

β€œTranslational Research Hub: KRAS G12C Inhibitor Program (GRX-417)”


🧭Program Overview

Program Code: GRX-417 Indication: Non-Small Cell Lung Cancer (NSCLC) Target: KRAS G12C mutation
Stage: Phase II Clinical Trials

🎯 Objectives

  • Improve progression-free survival vs standard of care
  • Identify biomarker-driven responder subgroups
  • Optimize dosing strategy

πŸ‘₯ Cross-Functional Teams

  • Discovery Biology
  • Translational Medicine
  • Clinical Development
  • Regulatory Affairs

πŸ”„ Notebook Purpose

  • Centralize all research, clinical, and translational insights
  • Track experiments + trial outcomes
  • Align across departments
  • Publish sanitized insights externally (Notearama layer)

Index

SECTION 1: πŸ”¬ Preclinical Research
SECTION 2: πŸ§ͺ Clinical Trial Operations
SECTION 3: 🧬 Biomarkers & Translational Insights
SECTION 4: πŸ“Š Data Analysis & Results
SECTION 5: πŸ“ Regulatory & Submission
SECTION 6: πŸ§‘β€πŸ€β€πŸ§‘ Internal Collaboration
SECTION 7: 🌍 External Insight Layer (Notearama)

 ]]> πŸ“‚ SECTION 7: 🌍 External Insight Layer (Notearama) 20260427T225831Z 20260501T215627Z David Nagy
β€Š

πŸ“„ β€œWhat We’re Learning About KRAS G12C Therapies”

  • Simplified, publishable insights

πŸ“„ Oncology Trends Brief

  • Industry-wide developments

πŸ“„ Thought Leadership Posts

  • Authored by team leads
πŸ‘‰ This is where pharma companies can:
  • Build scientific authority
  • Attract partners
  • Surface research to AI/search

πŸ’₯ Why This Works (Pharma Angle)

  • Breaks silos between research + clinical + regulatory
  • Replaces fragmented systems (SharePoint, PDFs, slide decks)
  • Enables continuous knowledge flow vs static reports


Back to Index
 ]]> πŸ“‚ SECTION 1: πŸ”¬ Preclinical Research 20260427T225045Z 20260501T215522Z David Nagy
β€Š

πŸ“„ Target Biology Overview

  • KRAS mutation pathways
  • Mechanism of action (GRX-417)
  • Competitive landscape

πŸ“„ In Vitro Studies

  • Cell line experiments
  • Drug potency metrics (IC50)
  • Comparative results

πŸ“„ In Vivo Models

  • Mouse model studies
  • Tumor shrinkage data
  • Toxicity observations

πŸ“„ Preclinical Conclusions

  • Go/no-go decisions
  • Risks identified


Back to Index
 ]]> πŸ“‚ SECTION 2: πŸ§ͺ Clinical Trial Operations 20260427T225525Z 20260501T215516Z David Nagy
β€Š

πŸ“„ Trial Design – Phase II

  • Inclusion/exclusion criteria
  • Endpoints
  • Dosing arms

πŸ“„ Site Activation Tracker

  • Trial sites
  • Enrollment status

πŸ“„ Patient Enrollment Dashboard

  • Total enrolled
  • Demographics
  • Dropout rates

πŸ“„ Adverse Events Log

  • Categorized by severity
  • Frequency trends


Back to Index
 ]]> πŸ“‚ SECTION 3: 🧬 Biomarkers & Translational Insights 20260427T225603Z 20260501T215511Z David Nagy
β€Š

πŸ“„ Biomarker Strategy

  • Genetic markers tracked
  • Hypotheses

πŸ“„ Patient Stratification Analysis

  • Responders vs non-responders
  • Molecular profiles

πŸ“„ Tissue & Sample Analysis

  • Biopsy results
  • Longitudinal changes


Back to Index
 ]]> πŸ“‚ SECTION 4: πŸ“Š Data Analysis & Results 20260427T225723Z 20260501T215503Z David Nagy
β€Š

πŸ“„ Interim Results (Rolling)

  • Efficacy metrics
  • Kaplan-Meier curves
  • Statistical significance

πŸ“„ Safety Profile Summary

  • Side effects vs competitors
  • Risk-benefit analysis

πŸ“„ Competitive Benchmarking

  • Compared to Amgen / Mirati therapies
  • Market positioning


Back to Index
 ]]> πŸ“‚ SECTION 5: πŸ“ Regulatory & Submission 20260427T225734Z 20260501T215457Z David Nagy
β€Š

πŸ“„ FDA Interaction Log

  • Meeting summaries
  • Feedback

πŸ“„ IND / NDA Documentation

  • Key documents
  • Submission timeline

πŸ“„ Risk Mitigation Plans

  • Safety concerns
  • Regulatory strategies


Back to Index
 ]]> πŸ“‚ SECTION 6: πŸ§‘β€πŸ€β€πŸ§‘ Internal Collaboration 20260427T225753Z 20260501T215449Z David Nagy
β€Š

πŸ“„ Weekly Program Sync Notes

  • Cross-team updates
  • Decisions

πŸ“„ Open Questions Tracker

  • Scientific unknowns
  • Operational blockers


Back to Index
 ]]>